Amarin Corporation (AMRN) New Label Likely to Make Acquirers Less Enthusiastic, Oppenheimer Reiterates Underperform
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Underperform rating and $8.00 price target on Amarin Corporation (NASDAQ: AMRN) after Friday's FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
